Kevzara (Sarilumab)

Sarilumab is a monoclonal antibody that binds to both soluble and membrane‑bound interleukin‑6 receptors. By blocking these receptors, it prevents IL‑6 from triggering downstream inflammatory signaling, thereby decreasing the immune‑mediated processes that drive rheumatoid arthritis.

The prescribed dose of Kevzara is determined by the treating physician based on the patient’s clinical condition, weight, and response to therapy. The medication is supplied as a 150 mg prefilled syringe for subcutaneous injection, and dosing frequency is set by the healthcare professional.

The safety of Kevzara in pregnancy and lactation has not been established. It is classified as pregnancy category unknown, and the drug should only be used if the potential benefit justifies the potential risk to the fetus or infant. Women should discuss alternatives with their physician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details and necessary import documentation.

Kevzara (sarilumab) and other IL‑6 pathway blockers such as tocilizumab share a similar mechanism of blocking IL‑6 signaling. Differences lie in dosing schedules, molecular structure, and specific regulatory approvals. Clinical choice depends on physician assessment of efficacy, safety profile, patient preference and formulary considerations.

Kevzara must be stored refrigerated between 2 °C and 8 °C. Keep the prefilled syringes in their original packaging, protect them from light, and avoid freezing or shaking. Do not use the product if it has been exposed to temperatures outside this range.

Kevzara is given as a subcutaneous injection using the prefilled 150 mg syringe. The injection is typically performed by a healthcare professional in a clinical setting, following aseptic technique. The injection site is usually the abdomen or thigh, and the frequency is determined by the prescriber.

The most serious risks include severe infections (bacterial, fungal, viral), gastrointestinal perforation, and rare but life‑threatening allergic reactions such as anaphylaxis. Patients should be monitored closely for signs of infection, abdominal pain, or hypersensitivity, and treatment should be discontinued if serious adverse events occur.

Kevzara should not be used in patients with active serious infections, known hypersensitivity to sarilumab or any component of the formulation, or in those receiving live or attenuated vaccines. Caution is also advised for individuals with uncontrolled liver disease, low neutrophil counts, or severe immunosuppression.